Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumour with an NF1 Mutation Responding to Trametinib: A Case...

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Malignant peripheral nerve sheath tumours (MPNSTs) are rare and aggressive cancers.
• Genomic alterations, particularly in the neurofibromatosis type 1 (NF1) gene, are implicated in MPNST development.
• Activation of the RAS-RAF-MEK-ERK signalling pathway is a common consequence of NF1 alterations in MPNSTs.

Observation:

• A patient was diagnosed with a sporadic MPNST.
• The patient's tumour exhibited an identified NF1 gene alteration.
• The RAS-RAF-MEK-ERK signalling pathway was presumed to be activated due to the NF1 alteration.

Findings:

• The patient was treated with trametinib, a targeted therapy.
• Trametinib acts as an inhibitor of MEK1 and MEK2, key components of the RAS-RAF-MEK-ERK pathway.
• The treatment with trametinib was successful in managing the patient's sporadic MPNST.

Implications:

• Trametinib demonstrates potential as a targeted therapeutic option for sporadic MPNSTs with NF1 alterations.
• This case highlights the importance of identifying specific genomic alterations for personalized cancer treatment.
• Further research into MEK inhibitors may lead to improved outcomes for MPNST patients.